| 1 |
33856277 | Phase 1b/2 study of ibrutinib and lenalidomide with dose-adjusted EPOCH-R in patients with relapsed/refractory diffuse large B-cell lymphoma. | 2021 Sep |
1 |
| 2 |
33946867 | Integration of Metabolomics and Gene Expression Profiling Elucidates IL4I1 as Modulator of Ibrutinib Resistance in ABC-Diffuse Large B Cell Lymphoma. | 2021 Apr 29 |
2 |
| 3 |
28592763 | Malignant lymphoma: pathophysiology and current therapy. | 2017 |
1 |
| 4 |
27904766 | The role of PIM1 in the ibrutinib-resistant ABC subtype of diffuse large B-cell lymphoma. | 2016 |
4 |
| 5 |
26193343 | Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma. | 2015 Aug |
3 |
| 6 |
22698399 | Exploiting synthetic lethality for the therapy of ABC diffuse large B cell lymphoma. | 2012 Jun 12 |
1 |